On August 9, 2024, the "Beijing Pharmaceutical Innovation and Investment Development Seminar and the CICC-R&G Investment Fund Establishment Ceremony", jointly hosted by the Tongzhou District People’s Government of Beijing Municipality, R&G PharmaStudies Co., Ltd., and CICC Capital, was successfully held at the Beijing International Wealth Center.

Meng Jingwei,  Party Secretary of Tongzhou District Committee; Wu Kong'an, Member of the Standing Committee of the District Committee and Deputy District Mayor; Yu Junping, Deputy Secretary of the Political and Judiciary Commission under the District Committee; Lin Wei, Assistant of the District Mayor and Government-appointed Expert; Li Pengyue, Deputy Director of the Division of Policies & Regulations of the Beijing Municipal Medical Products Administration; Xu Yicheng, Member of the Party Committee and Management Committee of CICC; Zhu Ce, Deputy Secretary of the Party Committee and General Manager of Anhui Provincial Investment Group Holding Co., Ltd.; Wu Jie, Chairman of R&G PharmaStudies Co., Ltd.; Li Ning, Vice President of the National Cancer Center and Vice President of the Cancer Hospital, Chinese Academy of Medical Sciences; Dr. Chen Gang, Chief Scientific Officer of R&G; Professor Hu Bei, Chief Clinical Pharmacologist of R&G; as well as nearly 200 representatives from the Tongzhou District People's Government, pharmaceutical enterprises, and investment institutions attended the event. They jointly witnessed the establishment of the CICC-R&G Investment Fund and explored new opportunities and challenges in pharmaceutical innovation and investment.

CICC R&G Shenghe (Beijing) Equity Investment Partnership (Limited Partnership) (abbreviated as "CICC-R&G Investment Fund") is a medical industry direct investment fund jointly initiated and established by CICC Capital and R&G PharmaStudies Co., Ltd.

CICC Capital has extensive equity investment experience and an outstanding historical performance in the medical field. Since its establishment, R&G has been committed to providing full-chain clinical CRO services to global innovative pharmaceutical and medical device companies. The CICC-R&G Investment Fund is a collaboration between financial capital and industrial capital, focusing on investments in the field of innovative pharmaceuticals and medical devices. The establishment of the fund will help promote the integration of the medical and financial sectors, industry and capital, assisting the full-chain development of the pharmaceutical industry.

Figure 1: Group Photo of Guests

Figure 2: Party Secretary of Tongzhou District Committee Meng Jingwei attended the event

Establishment of the Fund Opens a New Chapter in Pharmaceutical Investment

At the beginning of the event, speeches were delivered by Wu Kong'an, Member of the Standing Committee of the District Committee and Deputy District Mayor; Xu Yicheng, Member of the Party Committee and Management Committee of CICC; Deputy Secretary of the Party Committee and General Manager of Anhui Provincial Investment Group Holding Co., Ltd.; and Wu Jie, Chairman of R&G.

Figure 3: Speech by Wu Kong'an, Member of the Standing Committee of the District Committee and Deputy District Mayor

Figure 4: Speech by Xu Yicheng, Member of the Party Committee and Management Committee of CICC

Figure 5: Speech by Zhu Ce, Deputy Secretary of the Party Committee and General Manager of Anhui Provincial Investment Group Holding Co., Ltd.

Figure 6: Speech by Wu Jie, Chairman of R&G

At the establishment ceremony, Tong Xuanzi, Managing Director of CICC Capital and Head of the CICC-R&G Investment Fund; Zhao Qian, Chief Financial Officer of R&G PharmaStudies Co., Ltd.; Gao Zhan, Managing Director of Beijing Municipal Administrative Center Industrial Guidance Fund; Zeng Ying, Deputy General Manager of Beijing Guorun Xintong Investment Development Co., Ltd.; and Li Hongyan, Deputy General Manager of Anhui Provincial Railway Development Fund Co., Ltd., jointly attended the fund's establishment ceremony on behalf of all investors.

Figure 7: Group photo of guests at the signing ceremony

Keynote Speeches: Insights into the Industry's Future

Mr. Zhang Wenlang, Managing Director and Chief Macro Analyst of CICC, delivered a speech titled "Positioning for the 'Great Transformation'", sharing his in-depth interpretation of the macroeconomic and capital market situation.

Figure 8: Mr. Zhang Wenlang, Chief Macro Analyst of CICC, delivered the keynote speech

Dr. Li Ning, Vice President of the National Cancer Center and Vice President of the Cancer Hospital, Chinese Academy of Medical Sciences, shared the current status and outlook of clinical development of new drugs in China, revealing the latest trends and opportunities in new drug R&D.

Figure 9: Dr. Li Ning, Vice President of the National Cancer Center and Vice President of the Cancer Hospital, Chinese Academy of Medical Sciences, delivered the keynote speech

Mr. Li Pengyue, Deputy Director of the Division of Policies & Regulations of the Beijing Municipal Medical Products Administration, and Mr. Wu Kong'an, Member of the Standing Committee of the District Committee and Deputy District Mayor, provided detailed introductions on the policies supporting innovative development of the biopharmaceutical industry in Beijing and the development status of the biopharmaceutical industry in Beijing's city sub-center, showcasing Beijing's advantages and achievements in promoting the development of the biopharmaceutical industry.

Figure 10: Mr. Li Pengyue, Deputy Director of the Division of Policies & Regulations of the Beijing Municipal Medical Products Administration, delivering the keynote speech

Roundtable Discussions: Seeking New Directions for the Industry

The subsequent roundtable forum sessions were even more exciting. The first forum centered on "Navigating Cycles: New Directions in Innovative Medical Industry Investment". Mr. Zhang Xu, Executive General Manager of CICC Capital, served as the moderator, engaging with investment elites from Shougang Fund, Vivo Capital, Legend Capital, Med-Fine Capital, and other investment institutions to discuss new trends and opportunities in medical industry investment.

Figure 11: Guests of Roundtable Discussion I

The second forum focused on "New Models and Breakthroughs in Collaborative Development of the Innovation Ecosystem Chain". The Chief Scientific Officer of R&D acted as the moderator and, together with leaders from companies such as Innogen Pharmaceutical, Biostar Pharmaceuticals, Weidejie Biotechnology, and Nanjing Zenshine Pharmaceuticals, jointly explored new models for constructing and collaboratively developing the innovation ecosystem chain.

Figure 13: Guests of Roundtable Discussion II

The successful conclusion of the seminar and the grand launch of the CICC-Nuosige Investment Fund have jointly opened a new chapter in the field of pharmaceutical innovation and investment. The establishment of the fund will help promote the integration of healthcare and finance, industry and capital, injecting new vitality into the full-chain development of the pharmaceutical industry and the development of regional industrial clusters.